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Abstract
Background: Thymoma is a T cell neoplasm arising from the thymic epithelium that due to its immunological role, frequently
undercover derangements of immunity such a tumors and autoimmune diseases.
Methods:Herein, we report, to the best of our knowledge, the first description of an association between thymoma and adult onset
Still disease (AOSD) in a 47-year-old man. The first one was occasionally detected 4 years later the diagnosis of AOSD, and surgically
removed via right lateral thoracotomy. Histology confirmed an encapsulated thymic tumor (type AB sec. WHO-classification).
Results:The AOSDwas particularly resistant to the therapy, requiring a combination of immunosuppressant followed by anti-IL1R,
that was the only steroids-sparing treatment capable to induce and maintain the remission. The differential diagnosis was particularly
challenging because of the severe myasthenic-like symptoms that, with normal laboratory tests, were initially misinterpreted as
fibromyalgia. The pathogenic link of this association could be a thymus escape of autoreactive T lymphocytes causing autoimmunity.
Conclusion:Clinicians should be always include the possibility of a thymoma in the differential diagnosis of an unusual new onset of
weakness and normal laboratories data, in particular once autoimmune disease is present in the medical history.
Abbreviations: AOSD = adult onset Still disease, CRP =C-reactive protein, CT/PET = computed tomography/Positron emission
tomography, FDG = fluoro-2-deoxy-D-glucose, MG = myasthenia gravis, SUV = standard uptake value.
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Adult onset Still disease (AOSD) is a rare autoinflammatory
condition,[1–3] initially described by Bywaters in 1971.[4]
Nowadays, it is defined by a panel of clinical and laboratory
criteria of whom the most widely accepted are those of
Yamaguchi.[5] These include 4 major and 4 minor criteria.
Diagnosis is madewhen there are 5 ormore criteria which include
at least 2 major criteria. In current clinical practice, daily fever
and arthromyalgias are almost mandatory and in vast majority of
the patients these symptoms are accompanied by elevated acuteEditor: Leonidas G. Koniaris.
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1phase reactants, included hyperferritinemia (>5000mg/L) on
absence of specific markers of disease. Other symptoms, like
lymphadenopathy, splenomegaly, sore throat, pleuritis, pneu-
monitis, or pericarditis, are also frequently reported.[6,7]
Aspecific symptoms and signs of AOSD require the exclusion
of infections and neoplasm since a paraneoplastic AOSD-like
syndrome in the course of solid tumor, and hematopoietic
malignancy have been reported. However, other case reports
suggest the presence of a true AOSD mostly preceding
malignancy of an average of 9 months. It is controversial
whether the presence of AOSD could be coincidental or in some
way related to the subsequent neoplasm onset.[8]
Herein, we report a challenging case of a 47-year-old man who
developed a thymic epithelial tumor (thymoma AB sec. WHO-
Classification[9]), 4 years after the initial diagnosis of AOSD.
We may speculate on the fact that the underlying thymoma
probably represents the true trigger of the preceding AOSD;
indeed, it is well known that besides myasthenia gravis (MG),
other autoimmune disorders may occur in thymoma patients and
that over two-thirds of these autoimmune disorders occurred
before thymoma resection.
Among these autoimmune disorders a co-occurrence between
thymoma and AOSD has never reported since now in the
literature, to our best knowledge.2. Case report
In September 2010, a 46-year-old man was admitted in medicine
department for arthromyalgias, remitting fever up to 39°C,
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and papules on the trunk; all the symptoms gradually onset 1
month before. Laboratory profile revealed neutrophilic leukocy-
tosis 15,000 nL (nv 2000–8000 nL), Hb 10.5mg/dL, C-reactive
protein (CRP) 15.66mg/dL (nv 0.05–0.30), erythrocyte sedi-
mentation rate (ESR) 123mm/h (nv < 30mm/h), and ferritin
5381ng/mL (nv 25–350ng/mL). The following tests resulted
negative: procalcitonin, repeated blood and urine cultures,
antibodies to parvovirus B19, toxoplasma, rubivirus, cytomega-
lovirus, herpes viruses type 1 and 2, rickettsia, Widal–Wright
reaction, rheumatoid factor, Waaler–Rose, C3, C4, chest X-ray,
and ultrasound evaluation of the abdomen.
The start of corticosteroid treatment (oral prednisone at the
dose of 25mg t.i.d.) resulted in a gradual subside of the
symptoms; 1 month later, in the subsequent rheumatological
control, CRP was 0.07mg/dL, ferritin 487ng/mL, and ESR 20
mm/h. Methotrexate 10mg/wk was shortly added as a steroid
sparing agent. In December 2011, at the dose of 25mg/d of
prednisone, the patient got worst with increasing artrhalgias and
subjective poor conditions, although CRP and ESR levels were in
the normal ranges. In this occasion, leflunomide 20mg/d was
added to methotrexate and prednisone. Physical well-being was
obtained only maintaining prednisone over 17.5mg/d. Hence, in
April (7 months after the initial diagnosis), the Anakinra 100mg/
d (anti-IL1R) replaced MTX and LF; at this moment a further
chest X-ray did not revealed any radiological abnormalities;
moreover, laboratory tests were normal: CRP: 0.6mg/dL
(nv 0.05–0.30) and ESR: 40mm/h (nv < 30).
In September 2012, despite an unremarkable laboratory
profile, the patient complained muscle ache and weakness on
his legs. A complex diagnostic work-up examination was started
but all the examinations and visits (transthoracic echocardio-Figure 1. Radiologic evaluation (A and B): the chest CT-scan showed a lobulated
FDG PET/CT scan (C) revealed a mild uptake of the radiotracer (SUVmax: 3.2)
encapsulated thymic tumor (type AB). CT = computed tomography, FDG = fluor
uptake value.
2gram, magnetic resonance imaging of lumbar spine, magnetic
motor evoked potentials, neurosurgical and cardiological
examinations) did not found any pathological signs. On April
2013, neurological assessment was within the limits but due to
the subjective weakness after a sustained walk and the episodic
lowering of the speech, we investigated the presence of
antiacetilcholin receptors with a negative result. In November
2013, the patient’s complains were hence dismissed as severe
fibromyalgia and treated with selective serotonin receptor
inhibitors and gabapentin.
About 1 year later (October 2014), a chest computed
tomography (CT) scan was performed as part of the radiological
surveillance of an antibiotic-resistant pneumonia. A paracardiac
solid mass was identified (Fig. 1A and B) and a CT/Positron
emission tomography (PET) scan showed that the mass had a
mild 18F- fluoro-2-deoxy-D-glucose (FDG) uptake (standard
uptake value [SUV]-max 3.4, Fig. 1C) without specific
suggestions about its nature. The lesion was surgically removed
via right lateral thoracotomy and definitive histology was
indicative of an encapsulated thymic tumor (type AB sec.
WHO-classification, Fig. 1D). No adjuvant therapies were
recommended according with histology and staging of disease
(no capsular invasion). In January 2016, the patient reported to
be in good condition, the myalgias and weakness were subsided
and he is still on Anakinra treatment to maintain the remission of
AOSD.
3. Discussion
Thymomas are rare neoplasms with an overall incidence in the
United States of 0.15 cases per 100,000 person-year.[10] From a
histological point of view, most thymomas are composed of apara-cardiac mediastinal mass measuring 51mm of maximum diameter; 18F
at this level; pathological evaluation (D) showed the presence of an epithelial
o-2-deoxy-D-glucose, PET = Positron emission tomography, SUV = standard
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lymphocytes, with the proportion among them varying widely
from case to case.[11] There is a certain body of evidence
demonstrating that the thymus plays a central role in the immune
system, because it is the site of maturation for T cells.[12] Indeed,
the thymus’ primary functional role concerning the immunologi-
cal system is to process the T-lymphocyte selection and
maturation (the so-called “negative selection process”). In a
normal working condition, only self-tolerant and immune-
surveillant (against antineoplastic cells) T-lymphocytes are
released systematically from the thymus.[13] Therefore, consider-
ing the role of immune-surveillance played by the thymic gland, it
emerges why thymic neoplasms are associated with immunodefi-
ciency and autoimmune disorders. In detail, among human
neoplasms, thymomas are associated with the highest frequency
with paraneoplastic autoimmune disorders.[11]
Even excluding MG (the most common autoimmune disease
associated with thymomas), a wide variety of other autoimmune
conditions are associated with epithelial thymic tumors, of which
the most common are hematological (aplastic anemia, pure red
cell aplasia, and Good syndrome), neurological (plymyositis,
neuromyotonia, limbic encephalitis, and psychosis/sleep disor-
ders), cutaneous (pemphigus, vitiligo, alopecia, and lichen), and
generic ones (systemic lupus erythematosus, thyroiditis, ulcera-
tive colitis, and glomerulonephritis).
On the other hand, AOSD is a rare autoimmune disease
characterized primarily by a clinical triade (daily spiking daily
fever, arthritis, and cutaneous rash). Considering the absence of a
definitive diagnostic test, the diagnosis of AOSD is purely based
on clinical examination, and often necessitates the arduous
exclusion of potential mimickers such as infectious, autoimmune
or autoinflammatory diseases and neoplasms; in particular, the
exclusion of malignancy is of special concern, and all malignant
diseases especially lymphomas, solid cancers, and myeloprolifer-
ative disorders should be taken into account in this sense.
We have herein reported a challenging case of a young man
who presented with a thymoma 4 years after the clinical and
laboratoristic diagnosis of AOSD according to the Yamaguchi
criteria.[5] There is an ongoing debate about the co-occurrence of
AOSD and solid cancers; it is controversial whether it is a
paraneoplastic syndrome or just a coincidence. Indeed, it is not
easy to distinguish them. As reported byHofheinz et al,[14] in case
a neoplastic disease is diagnosed in a patient, who had been
diagnosed with AOSD, various categories of relationship are
possible: a true paraneoplasia, a misinterpretation of tumor
symptoms for AOSD, mere coincidence, or a monoclonal
malignant proliferation of immune cells due to strong, initially
polyclonal autoimmune proliferation, or during immunosup-
pressive therapy.
One can speculate that if the corticosteroid treatment could
resolve the symptoms, the possibility of coincidence is more
reasonable. However, it is not always true in the case of AOSD,
considering that generally patients necessitate agents other than
corticosteroids, such as anti-TNFs, interleukin-1, and 6 blockers,
to resolve their symptoms. On the contrary, given the fact that
paraneoplastic syndromes occur due to the effects of certain
mediators, these mediators might also be involved in the
development of paraneoplastic AOSD. Therefore, the achieving
of a good clinical response to corticosteroids in such scenario
would not be an unexpected situation.
In a recent review performed byHofheinz et al,[14] the pertinent
literature was retrospectively evaluated using the criteria of
Yamaguchi,[5] Fautrel,[15] and Crispin;[16] a total of 36 patients3fulfilled at least 1 of these sets of criteria and therefore are
considered malignancy-associated AOSD. In 72% of all cases,
AOSD-related symptoms preceded the tumor diagnosis (by a
median of 9 months) whereas in few cases (8 patients), the onset
of AOSD symptoms and the detection of a neoplasm occurred
simultaneously. Finally only in 2 cases, they appeared after the
detection of a malignancy or during its treatment.
In the present case, considering the very indolent behavior of
thymoma WHO-Class AB,[17] we may speculate that the
neoplasm could be occurred before or synchronously with
AOSD but “missed” at physical examination at that time. In fact,
very often the diagnosis of thymoma is incidental during
routinary investigations performed for other reasons; indeed,
such neoplasms are often not related with specific symptoms,
especially in early-stage tumors. Since some malignancies could
not be detected at the time of the initial diagnostic work-up
examination, the present case may emphasize the possibility to
consider the presence of an underlying neoplasm, not only at
initial evaluation, but also during the follow-up.
Commonly encountered clinical (fever, sore throat, arthralgia,
arthritis, and rash) and laboratory (leukocytosis, increased acute
phase reactants, and hyperferritinemia) features of malignancy
associated with AOSD were similar to primary AOSD.
Solid tumors originated from a wide variety of organs and
tissue types with ductal breast cancer (n=4) and nonsmall cell
lung cancer (n=3) being the most frequent histological entities. In
12 of all 18 patients with solid tumors, metastatic spreading was
already described at the time of diagnosis.
There is no mention of epithelial thymic tumor in association
with AOSD and this datum arouses, in our opinion, a certain
interest. Indeed, as remarked above, among human neoplasms,
thymomas are associated with the highest frequency with
paraneoplastic autoimmune disorders.
Since 2009, there have been 5 case reports, which describe
PET-CT as the key to diagnosis in maAOSD. In these patients, the
malignant process was revealed by an increased tracer uptake.
In the present case, the 18F-FDG PET/CT showed a light
uptake of the tracer at the level of the mediastinal mass, as a
consequence of the very indolent behavior (and consequent low
mitotic count) of this tumor. In fact there is a certain body of
evidence[18,19] suggesting that thymomas A or AB presented with
very low uptake values at 18F-FDG PET/CT whereas an intense
uptake may be expected in more aggressive thymic tumors.
Concerning the treatment, corticosteroid therapy is usually the
first therapeutic option in AOSD-patients. In our case, at the time
of clinical diagnosis of AOSD, a corticosteroid therapy obtained a
preliminary substantially complete remission of the clinical and
laboratories’ abnormalities. Later on, this positive effect fainted
and the Anakinra was required to obtain a prolonged remission.
Reviewing the literature, Hofheinz[14] observed that among 36
patients with malignancies associated with ASOD, a pharmaco-
logical therapy based on corticosteroids has been given to 31
patients achieving a clinical response in 19 of them (12 complete
response and 7 partial response). There is no clear information
regarding the clinical course of AOSD according with the
treatment of the associated malignancy. In the present case, we
observed a remarkable improvement of the patient’s condition
with the initial steroids dosage. However, the initial necessity to
escalate the treatment to Methotrexate and Leflunomide, and the
following switch to Anakinra, clearly supports the presence of a
2 different conditions; probably in causative association more
than mere coincidence among the 2. In fact it is well known
that the high prevalence of autoimmune diseases co-existing with
[2] Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s
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malignancy correlated with onset Still disease or is it just a
coincidence?), we should accurately investigate the frequency of
both entity to estimate the probability of a causal association. As
correctly remarked in,[14] it is hard to get to accurately estimate
the real frequency of the malignancies associated with AOSD.
After a review of the clinical records coming from the 7 larger
published cohorts of AOSD patients, the authors supposed a
probable frequency well below 2% of ASOD associated with
malignancy. In the present case, we report an association between
2 different very rare disease; overall incidence of the thymoma is
estimated in United States of 0.15 cases per 100,000 person-year
while the annual incidence of AOSD in Europe consists around of
0.4/100,000 adults. These data seem to support the hypothesis
that causative association (thymoma related to the AOSD onset)
more than mere coincidence could exist and deserve specific
confirmatory analysis.
Finally, in almost all published malignancy-associated AOSD
cases,[14] these occurred simultaneously with the underlying
neoplasm or its relapse, and probably the same occurred in the
present case supporting the hypothesis that thymoma represents a
condition favoring the onset of autoimmune derangement.4. Conclusions
Adult onset Still disease (AOSD) is a rare autoinflammatory
condition, defined by a panel of clinical and laboratory criteria.
Several solid and nonsolid neoplasms have been reported in
association with AOSD but the relationship between the
neoplasm and autoinflammatory disease has not been yet
clarified. Herein we have reported a unique case of thymic
neoplasm occurring 4 years after the diagnosis of AOSD. It could
be reasonable to assume that the underlying thymoma probably
represents the true trigger of the preceding AODS, considering
that besides MG, other autoimmune disorders occur in thymoma
patients, often anticipating the final diagnosis of thymoma.References
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